- Tytuł :
-
Intravesical nadofaragene firadenovec gene
therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. - Autorzy :
- Źródło :
- The Lancet. Oncology [Lancet Oncol] 2021 Jan; Vol. 22 (1), pp. 107-117. Date of Electronic Publication: 2020 Nov 27.
- Typ publikacji :
- Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
- MeSH Terms :
-
Drug Resistance, Neoplasm*
Genetic Therapy */adverse effectsGenetic Therapy */mortalityGenetic Vectors*
Adenoviridae/*genetics
BCG Vaccine/*administration & dosage
Carcinoma in Situ/*therapy
Interferon alpha-2/*genetics
Urinary Bladder Neoplasms/*therapy
Administration, Intravesical ; Aged ; BCG Vaccine/adverse effects ; Carcinoma in Situ/genetics ; Carcinoma in Situ/mortality ; Carcinoma in Situ/pathology ; Disease Progression ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Invasiveness ; Neoplasm Recurrence, Local ; Time Factors ; Treatment Outcome ; United States ; Urinary Bladder Neoplasms/genetics ; Urinary Bladder Neoplasms/mortality ; Urinary Bladder Neoplasms/pathology -
Czasopismo naukowe